Essilor reported that after 1 year of an ongoing clinical trial, there was a more than 60% slowdown in myopia progression in children on average with the recently launched Stellest lens, compared to a single vision lenses.
Essilor launched the Stellest lens in the Wenzhou Medical University Eye Hospital in China in July. This will be continued with a broader roll-out in other hospitals in China, followed by several other countries. The ongoing 3-year clinical trial on 167 myopic children2 started in 2018 in Essilor’s joint Research and Development Center with its partner, the Wenzhou Medical University, in China. The 1-year results demonstrate strong evidence of the lenses’ effectiveness in slowing down myopia progression and promises to be Essilor’s best solution to fight myopia progression in children—in an aesthetic, efficient, safe, simple and easy to prescribe solution, according to a company news release.
Key interim findings after one year revealed:
● After 1 year, children wearing Stellest lenses saved more than half a diopter of myopia degree on average (more than 60% slow-down in myopia progression when compared to the control group wearing single vision lenses).
● After 1 year, eye elongation was prevented in 28% of the children wearing Stellest lenses, while eye elongation occurred in all the children wearing single vision lenses.
● 100% of children wearing Stellest lenses had clear vision, adapted to their new lenses within a week, and were as satisfied with their quality of vision as the children wearing single vision lenses.
“The interim results are impressive, confirming the positive impact of this solution on myopic children and making us fully confident that the Stellest lens will be one of the most effective myopia control spectacle lenses in the world,” Norbert Gorny, Co-Chief Operating Officer, Essilor International, said in the news release. “This lens will mark a new era of innovation in this field and is testament to one of the many ways in which Essilor continues to push the boundaries with innovation and technology, to tackle the myopia epidemic.”
1) Source: McKinsey research; China National Health Commission 2018 survey
2) The children in the study were between 8 and 13 years old and were divided into a treatment group equipped with Stellest™ lenses and a control group with single vision lenses.